Black Diamond Therapeutics, Inc. (BDTX) vs MaxCyte, Inc. (MXCT)
A side-by-side comparison of Black Diamond Therapeutics, Inc. and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BDTX
Black Diamond Therapeutics, Inc.
$1.80HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MXCT
MaxCyte, Inc.
$1.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BDTX vs MXCT
growth of $100 · dividends reinvested · last 5yBDTX -79.7% (-27.3%/yr)MXCT -93.6% (-42.4%/yr)BDTX compounded faster over this window
BDTX MXCT
BDTX vs MXCT: by the numbers
- •MXCT is the larger company ($117M vs $103M market cap).
- •BDTX is profitable (31.95% net margin) while MXCT runs a net loss (-114.77%).
Metrics side by side
Valuation
| Metric | BDTX | MXCT |
|---|---|---|
| P/S ratio | N/A | 3.76 |
| P/B ratio | 1.07 | 0.74 |
Profitability
| Metric | BDTX | MXCT |
|---|---|---|
| Gross margin | 99.54% | 79.43% |
| Operating margin | 28.39% | -137.12% |
| Net margin | 31.95% | -114.77% |
| ROE | -44.29% | -22.45% |
| ROIC | -47.54% | -19.83% |
Growth (annualized)
| Metric | BDTX | MXCT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 1.46% |
| Total return CAGR (5Y) | -24.47% | -37.32% |
Frequently asked
- Is BDTX or MXCT more profitable?
- BDTX runs the higher net margin — BDTX at 31.95% versus MXCT at -114.77%.
- How have BDTX and MXCT total returns compared?
- Over the past 5 years, BDTX delivered -24.47% and MXCT delivered -37.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.